Breaking News Instant updates and real-time market news.

SYNC

Synacor

$1.85

0.01 (0.54%)

, IEC

IEC Electronics

$7.20

-0.03 (-0.41%)

04:55
01/29/19
01/29
04:55
01/29/19
04:55

Noble Capital Markets to hold a conference

15th Annual Investor Conference: NobleCon15 will be held in Fort Lauderdale, FL on January 28-29.

SYNC

Synacor

$1.85

0.01 (0.54%)

IEC

IEC Electronics

$7.20

-0.03 (-0.41%)

MYO

Myomo

$1.66

0.01 (0.61%)

ALT

Altimmune

$3.20

-0.205 (-6.02%)

CPSH

CPS Technologies

$1.33

-0.12 (-8.28%)

SFE

Safeguard Scientifics

$9.55

-0.15 (-1.55%)

BTX

Ticker changed to LCTX

$0.89

-0.0402 (-4.31%)

ONTX

Onconova

$2.26

-0.15 (-6.22%)

ATNM

Actinium Pharmaceuticals

$0.54

-0.0199 (-3.59%)

EAST

Eastside Distilling

$5.88

-0.16 (-2.65%)

IDXG

Interpace Biosciences

$0.90

0.0599 (7.13%)

MIND

Mitcham Industries

$3.95

0.07 (1.81%)

GSL

Global Ship Lease

$0.83

-0.025 (-2.92%)

EGLE

Eagle Bulk Shipping

$4.16

-0.27 (-6.09%)

INSW

International Seaways

$17.37

-0.07 (-0.40%)

GLDD

Great Lakes Dredge

$7.08

-0.11 (-1.53%)

CTG

Computer Task Group

$4.62

0.19 (4.29%)

GNE

Genie Energy

$8.84

-0.04 (-0.45%)

MNKD

MannKind

$1.25

-0.035 (-2.72%)

  • 29

    Jan

  • 06

    Feb

  • 18

    May

SYNC Synacor
$1.85

0.01 (0.54%)

11/09/18
RSBL
11/09/18
DOWNGRADE
RSBL
Neutral
Synacor downgraded to Neutral from Buy at Rosenblatt
03/16/18
ADAM
03/16/18
DOWNGRADE
Target $3
ADAM
Hold
Synacor downgraded to Hold at Canaccord
As previously reported, Canaccord analyst Michael Graham downgraded Synacor (SYNC) to Hold from Buy following Q4 results. The analyst said the AT&T (T) revenue contribution was higher than expected, but the portal and advertising business ex-AT&T declined. He said the AT&T portal monetization is also being pushed out further as engagement remains a top priority. Graham said he sees limited downside at current levels, but the overall lower visibility leads to the downgrade. He lowered his price target to $3 from $6 on Synacor shares.
03/16/18
RSBL
03/16/18
NO CHANGE
Target $4.75
RSBL
Buy
Synacor showing signs of improvement outside AT&T, says Rosenblatt
Rosenblatt analyst Marshall Senk noted that Synacor's (SYNC) Q4 results met guidance despite the slower than expected pace of monetization from AT&T (T). Outside of AT&T, the company's other business areas continued to show signs of improvement, said Senk, who lowered his price target on Synacor to $4.75 from $5.50 but keeps Buy rating on the stock.
08/02/18
LSCM
08/02/18
NO CHANGE
Target $3
LSCM
Buy
Synacor shares are 'worth revisiting,' says Lake Street
Lake Street analyst Mark Argento says shares of Synacor (SYNC) are "worth revisiting" as the story becomes less about AT&T (T) and more about higher margin recurring revenues. The company posted another solid quarter, Argento tells investors in a post-earnings research note. He keeps a Buy rating on Synacor with a $3 price target.
IEC IEC Electronics
$7.20

-0.03 (-0.41%)

MYO Myomo
$1.66

0.01 (0.61%)

05/10/18
ROTH
05/10/18
NO CHANGE
Target $7
ROTH
Buy
Myomo price target lowered to $7 after 'challenging quarter' at Roth Capital
Roth Capital analyst Scott Henry said Myomo had a "challenging quarter" as its volume was below expectations and a reimbursement bottleneck is slowing its sales cycle. Following the report he reduced his FY18 revenue and EPS outlook, leading him to cut his price target on Myomo shares to $7 from $9. Henry maintains a Buy rating on Myomo.
05/14/18
HCWC
05/14/18
NO CHANGE
Target $12
HCWC
Buy
Final decision on Myomo Medicare codes could come in Q4, says H.C. Wainwright
H.C. Wainwright analyst Amit Dayal notes that Myomo announced that the Centers for Medicare & Medicaid Services has published a favorable preliminary decision regarding the company's application for Healthcare Common Procedure Coding System codes. Based on his experience, the analyst believes that a final decision to make these codes permanent could come as early as Q4 of 2018. Dayal reiterates a Buy rating and $12 price target on the shares.
03/09/18
ROTH
03/09/18
INITIATION
Target $9
ROTH
Buy
Myomo initiated with a Buy at Roth Capital
Roth Capital analyst Scott Henry started Myomo with a Buy rating and $9 price target on his belief that the MyoPro robotic arm brace offers meaningful benefits for the large market of individuals with partial upper extremity paralysis.
ALT Altimmune
$3.20

-0.205 (-6.02%)

CPSH CPS Technologies
$1.33

-0.12 (-8.28%)

SFE Safeguard Scientifics
$9.55

-0.15 (-1.55%)

07/26/18
FANA
07/26/18
DOWNGRADE
FANA
Equal-Weight
Safeguard Scientifics downgraded to Equal-Weight at First Analysis
07/26/18
07/26/18
DOWNGRADE
Target $17

Equal-Weight
Safeguard Scientifics downgraded on 'disappointing' exits at First Analysis
As previously reported, First Analysis analyst James Macdonald downgraded Safeguard Scientifics to Equal-Weight from Overweight citing its " disappointing" exits and write-downs and the need to repay all debt before distributions are made. While noting that several additional transactions are possible this year, Macdonald does not see visibility into any additional large cash return opportunities in the next 6-12 months, he tells investors. He lowered his price target for the shares to $17 from $18.
BTX Ticker changed to LCTX
$0.89

-0.0402 (-4.31%)

01/24/19
MAXM
01/24/19
INITIATION
MAXM
Buy
BioTime initiated with a Buy at Maxim
02/02/18
LSCM
02/02/18
INITIATION
Target $8
LSCM
Buy
BioTime initiated with a Buy at Lake Street
Lake Street analyst Bruce Jackson started BioTime with a Buy rating and $8 price target. The company may appear complex given its interdependent corporate structure, but there is reward for investors who can recognize the value creation underway at both BioTime and its minority investments, Jackson tells investors in a research note.
12/10/18
OPCO
12/10/18
INITIATION
Target $3.5
OPCO
Outperform
BioTime initiated with an Outperform at Oppenheimer
Oppenheimer analyst Kevin DeGeeter started BioTime with an Outperform rating and $3.50 price target. New management is transforming BioTime from a holding company of multiple technology platforms to a product development company "committed to allocating necessary resources to the most promising drug," OpRegen for the treatment of dry age-related macular degeneration, DeGeeter tells investors in a research note. He expects OpRegen to have peak end-market revenue of $1.3B.
01/24/19
MAXM
01/24/19
INITIATION
Target $3
MAXM
Buy
BioTime initiated with a Buy at Maxim
Maxim analyst Jason McCarthy initiated BioTime with a Buy rating and a price target of $3. The analyst notes that while the company's Renevia is moving towards approval for HIV-associated lipoatrophy in Europe, its more significant upside comes from the development of its allogeneic cell therapy OpRegen currently in development for dry age-related macular degeneration.
ONTX Onconova
$2.26

-0.15 (-6.22%)

10/11/18
MAXM
10/11/18
NO CHANGE
Target $16
MAXM
Buy
Onconova price target lowered to $16 at Maxim to reflect reverse stock split
Maxim analyst Jason MacCarthy lowered his price target on Onconova to $16 from $45 to reflect the impact of the company's 1-for-15 reverse stock split announced on September 25th which reduced the number of shares outstanding to 5.67M from 85.11M. McCarthy also keeps his Buy rating on the shares and notes that his bullish stance remains intact as the company's "rigosertib phase 3 program continues to enroll and timelines remain unchanged".
05/03/18
MAXM
05/03/18
UPGRADE
Target $3
MAXM
Buy
Onconova upgraded to Buy at Maxim on renewed Rigosertib investor focus
As reported earlier, Maxim analyst Jason McCarthy upgraded Onconova to Buy from Hold with a price target of $3. The analyst notes that investors' focus is shifting to Rigosertib now that the company's "financing roadblock has been cleared". McCarthy believes that "Rigosertib could emerge as the first targeted therapy approved for MDS based on the mechanism of action and both prior and emerging data".
05/02/18
MAXM
05/02/18
UPGRADE
MAXM
Buy
Onconova upgraded to Buy from Hold at Maxim
12/03/18
12/03/18
NO CHANGE

Onconova presents rigosertib with azacitidine data at ASH
Onconova Therapeutics announced the presentation of the efficacy and safety results of oral rigosertib in combination with azacitidine in patients with HR-MDS reported at an oral presentation during the American Society of Hematology, or ASH. Rigosertib, the company's lead compound, is being evaluated in both intravenous and oral forms. Seventy-four patients were treated with a median age of 69 years at nine clinical sites and received either 840 mg or 1,120 mg of oral rigosertib daily divided into two doses, in combination with a standard dose of injectable azacitidine. Of the 55 evaluable patients, 29 patients were treated with a daily dose of 1,120 mg of oral rigosertib, either 560 mg twice daily or 840 mg in the a.m. and 280 mg in the afternoon. Twenty-six patients were treated with 560 mg in the AM and 280 mg in the PM for the first three weeks of a four-week cycle. All patients also received 75 mg/m2/day SC or IV azacitidine during the second week of the four-week cycle. The median duration of treatment for the HMA naive and HMA failed patients was 7.8 and 4.9 months respectively. The median duration of response in these groups was 12.2 and 10.8 months, respectively. The overall response rate, or ORR, using the IWG 2006 criteria, in 29 HMA naive patients was 90%, including 10 patients with complete remission, or CR. Among the 26 evaluable HMA-failed patients the ORR was 54% including 8% CR or PR. The median time to initial and best response were 1 and 4 cycles in the HMA naive group and 2 and 5 cycles in the HMA failed group. The safety population received at least 1 dose of oral rigosertib. The combination was well tolerated. Other than genitourinary adverse events, or AEs, the AE profile was similar to those described for azacitidine alone in this patient population. Genitourinary AEs, including hematuria and dysuria were observed. A safety optimization strategy was implemented for the higher dose cohort of 1,120 mg of oral rigosertib. These strategies included earlier in the day administration of the PM dose, oral hydration, monitoring of urinary pH and mandatory bladder emptying at night. Collectively these strategies resulted in mitigation of the target genitourinary AEs, including reduction of genitourinary grade 3 AEs reported from an earlier cohort despite receiving a higher dose of oral rigosertib. In conclusion, oral rigosertib in combination with azacitidine was well tolerated in HMA naive and HMA failed HR-MDS patients. The combination produced an encouraging rate of overall response and complete remission in both groups. The safety optimization strategies and increased dose exploration of oral rigosertib in the combination is leading to the development of a pivotal Phase 3 trial in HMA and chemotherapy naive patients. Onconova plans to meet with the FDA to discuss the results of the Phase 2 trial and the planned Phase 3 trial, and to seek a special protocol assessment. The company has partnered rigosertib with SymBio Pharmaceuticals, for Japan and Korea, and with Pint Pharma for Latin American countries. Both partners have indicated their interest in participating in the proposed new pivotal Phase 3 trial by enrolling patients in their respective territories. SymBio is currently conducting Phase 1 studies with oral rigosertib in Japan and also participating in the Phase 3 global INSPIRE trial. The company is also actively seeking additional collaborations for rigosertib in other geographies.
ATNM Actinium Pharmaceuticals
$0.54

-0.0199 (-3.59%)

07/12/18
RILY
07/12/18
NO CHANGE
Target $3
RILY
Buy
Actinium price target raised to $3 from $2.75 at B. Riley FBR
B. Riley FBR analyst George Zavoico raised his price target for Actinium Pharmaceuticals to $3.00 from $2.75 and keeps a Buy rating on the shares. The company's new Phase I trial for Actimab-A MRDexpands its footprint in acute myeloid leukemia, Zavoico tells investors in a research note.
EAST Eastside Distilling
$5.88

-0.16 (-2.65%)

IDXG Interpace Biosciences
$0.90

0.0599 (7.13%)

03/08/18
HCWC
03/08/18
INITIATION
Target $3
HCWC
Buy
Interpace Diagnostics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Interpace Diagnostics with a Buy rating and $3 price target. The company's diagnostic offerings are differentiated in that PancraGEN has a positive predictive value significantly better than international guidelines for diagnosis of pancreatic malignancy, Selvaraju tells investors in a research note.
06/22/18
06/22/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Sunlands Online (STG) initiated with an Outperform at Credit Suisse. 2. Micron (MU) initiated with a Buy at Benchmark. 3. Interpace Diagnostics (IDXG) initiated with a Buy at Ladenburg. 4. Alteryx (AYX) initiated with an Outperform at Oppenheimer. 5. BioCryst (BCRX) initiated with a Neutral at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/22/18
LTCO
06/22/18
INITIATION
Target $2.25
LTCO
Buy
Interpace Diagnostics initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter started Interpace Diagnostics Group with a Buy rating and $2.25 price target. The analyst sees 20%-plus growth in 2018 driven by the company's thyroid test.
03/08/18
03/08/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tyler Technologies (TYL) initiated with a Neutral at DA Davidson. 2. Interpace Diagnostics (IDXG) initiated with a Buy at H.C. Wainwright. 3. Crispr Therapeutics (CRSP) initiated with an Outperform at JMP Securities. 4. Quanta Capital Hldgs (QNTA) initiated with an Outperform at Northland. 5. Genocea (GNCA) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
MIND Mitcham Industries
$3.95

0.07 (1.81%)

GSL Global Ship Lease
$0.83

-0.025 (-2.92%)

EGLE Eagle Bulk Shipping
$4.16

-0.27 (-6.09%)

07/25/18
MAXM
07/25/18
UPGRADE
Target $7.5
MAXM
Buy
Eagle Bulk Shipping upgraded to Buy from Hold at Maxim
Maxim analyst James Jang upgraded Eagle Bulk Shipping to Buy from Hold and raised his price target on the shares to $7.50 from $6.00.
10/03/18
RILY
10/03/18
INITIATION
Target $8.5
RILY
Buy
Eagle Bulk Shipping initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Liam Burke started Eagle Bulk Shipping with a Buy rating and $8.50 price target.
06/18/18
MSCO
06/18/18
INITIATION
Target $6.5
MSCO
Equal Weight
Eagle Bulk Shipping initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Fotis Giannakoulis initiated coverage of Eagle Bulk Shipping with an Equal Weight rating and $6.50 price target. Favorable dry bulk fundamentals, its strong management team and low levered balance sheet inspire confidence, but the dry bulk sector remains highly volatile and closely linked to Chinese commodity demand, Giannakoulis tells investors.
06/18/18
DNBM
06/18/18
INITIATION
DNBM
Buy
Eagle Bulk Shipping initiated with a Buy at DNB Markets
INSW International Seaways
$17.37

-0.07 (-0.40%)

09/25/18
09/25/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Wendy's (WEN) initiated with a Buy at BTIG. 2. BJ's Wholesale (BJ) initiated with a Buy at Northcoast. 3. Central Garden & Pet (CENT) initiated with a Neutral at JPMorgan. 4. International Seaways (INSW) initiated with a Buy at Stifel. 5. Welltower (WELL) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/01/18
JEFF
10/01/18
INITIATION
Target $30
JEFF
Buy
International Seaways initiated with a Buy at Jefferies
Jefferies analyst Randy Giveans started International Seaways with a Buy rating and $30 price target. Tanker demand growth is set to outpace tanker supply growth through at least 2020, Giveans tells investors in a research note. As a result. he believes the crude tanker market is now past the bottom and shipping rates should improve significantly in the coming quarters and years. The analyst calls International Seaways his top crude tanker pick.
11/09/18
RILY
11/09/18
INITIATION
Target $21.5
RILY
Neutral
International Seaways initiated with a Neutral at B. Riley FBR
B. Riley FBR analyst Liam Burke started International Seaways with a Neutral rating and $21.50 price target.
12/06/18
JEFF
12/06/18
NO CHANGE
Target $30
JEFF
Buy
International Seaways 'very attractive' play on tanker recovery, says Jefferies
After accompanying the management team in client meetings, Jefferies analyst Randy Giveans believes that International Seaways is a "very attractive" way to invest in the sustained tanker recovery "that has just begun." The recent improvement in the crude tanker market is only the beginning of what should be a multi-year recovery, Giveans tells investors in a research note. The analyst keeps a Buy rating on International Seaways with a $30 price target.
GLDD Great Lakes Dredge
$7.08

-0.11 (-1.53%)

CTG Computer Task Group
$4.62

0.19 (4.29%)

06/15/18
06/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. NV5 Global (NVEE) upgraded to Buy from Neutral at Sidoti. 2. Badger Meter (BMI) upgraded to Hold from Sell at Canaccord with analyst Chip Moore saying the company will continue to benefit from favorable demand for water/flow measurement and conservation technologies in the future, but he feels the current risk/reward is balanced. 3.Charles River (CRL) upgraded to Overweight from Sector Weight at KeyBanc with analyst Donald Hooker saying the stock is one of the best risk-reward stories in the biopharma outsourcing space heading into the second half of 2018. 4. Computer Task Group (CTG) upgraded to Outperform from Market Perform at Barrington with analyst Vincent Colicchio saying the valuation looks favorable following the recent pullback in the shares. 5. Spire (SR) upgraded to Outperform from Market Perform at Wells Fargo with analyst Sarah Akers saying the recent weakness in the shares provides an attractive entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/15/18
BRRR
06/15/18
UPGRADE
Target $9
BRRR
Outperform
Computer Task Group upgraded to Outperform from Market Perform at Barrington
Barrington analyst Vincent Colicchio upgraded Computer Task Group to Outperform saying the valuation looks favorable following the recent pullback in the shares. Since taking over in July 2016, CEO Bud Crumlish took several actions, including increased investment in the core staffing business and changes to compensation incentives to better align management with shareholders, which has the company's improved growth prospects, Colicchio tells investors in a research note. The analyst has a $9 price target for the stock.
GNE Genie Energy
$8.84

-0.04 (-0.45%)

MNKD MannKind
$1.25

-0.035 (-2.72%)

06/26/18
HCWC
06/26/18
NO CHANGE
Target $5
HCWC
Buy
MannKind gained 'new credibility' for Afrezza at ADA, says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat said MannKind materially increased Afrezza's relevance and gained "new credibility" with multiple data presentations, including a well-attended symposium and oral presentation, at the American Diabetes Association meeting that was just held. He called the event an "eye-opening experience" that showed Afrezza's defining differentiation is not that it is inhalable, but that it "really is the best meal-time insulin, full stop." Following the ADA event, Livnat reiterated his Buy rating and $5 target on MannKind shares.
08/03/18
HCWC
08/03/18
NO CHANGE
Target $4
HCWC
Buy
MannKind price target lowered to $4 from $5 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat lowered his price target for MannKind to $4 citing the company's "light" Q2 results. The analyst, however, still models for an Afrezza ramp in the second half of the year. He remains remain "very bullish long-term if the product can be resourced" and keeps a Buy rating on MannKind.
09/05/18
HCWC
09/05/18
NO CHANGE
Target $4
HCWC
Buy
MannKind valuation 'floor' raised with United deal, says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat says United Therapeutics (UTHR) is the "ideal partner" for MannKind (MNKD) to develop and commercialize technosphere treprostinil dry powder inhalation for pulmonary arterial hypertension. The deal announced yesterday represents additional validation of MannKind's "underappreciated" DPI and delivery platforms beyond Afrezza, Livnat tells investors in a research note. Importantly, the deal brings in non-dilutive financing, "raises the floor" on MannKind's valuation, and "offers a new path to potential long-term upside from here even if Afrezza never reaches the potential we think it deserves," Livnat writes. The analyst reiterates a Buy rating on MannKind shares with a $4 price target. The stock closed yesterday up 89%, or 98c, to $2.08.
06/07/18
HCWC
06/07/18
NO CHANGE
Target $5
HCWC
Buy
MannKind's treprostinil could be 'transformational asset,' says H.C. Wainwright
MannKind's (MNKD) announcement this morning of a successful Phase 1 completion of its Technosphere treprostinil dry powder inhalation for pulmonary arterial hypertension comes months ahead of schedule, H.C. Wainwright analyst Oren Livnat tells investors in a research note. The news is an important reminder that MannKind's inhalation drug delivery platforms offer potentially much more value than just Afrezza inhalable insulin, the analyst contends. He believes inhalable treprostinil, which is not yet in his model, could "ultimately prove a transformational asset." Livnat points out that United Therapeutics' (UTHR) pulmonary arterial hypertension treprostinil franchise is estimated to deliver over $1.1B of sales in 2018. The analyst keeps a Buy rating on MannKind with a $5 price target.

TODAY'S FREE FLY STORIES

INVH

Invitation Homes

$29.95

-0.04 (-0.13%)

18:47
11/18/19
11/18
18:47
11/18/19
18:47
Hot Stocks
Invitation Homes CEO sells 70K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$369.50

-2.05 (-0.55%)

, LUV

Southwest

$57.77

-0.03 (-0.05%)

18:44
11/18/19
11/18
18:44
11/18/19
18:44
Periodicals
Boeing to provide Southwest board with 737 MAX update this week, Reuters says »

Boeing (BA) this week…

BA

Boeing

$369.50

-2.05 (-0.55%)

LUV

Southwest

$57.77

-0.03 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 23

    Jan

GBDC

Golub Capital

$17.79

0.045 (0.25%)

18:42
11/18/19
11/18
18:42
11/18/19
18:42
Upgrade
Golub Capital rating change  »

Golub Capital upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

GM

General Motors

$36.62

-0.25 (-0.68%)

, TM

Toyota

$143.53

-0.76 (-0.53%)

18:42
11/18/19
11/18
18:42
11/18/19
18:42
Periodicals
CA to halt purchase of GM, Toyota, Fiat Chrysler vehicles, Reuters reports »

The state of California…

GM

General Motors

$36.62

-0.25 (-0.68%)

TM

Toyota

$143.53

-0.76 (-0.53%)

FCAU

Fiat Chrysler

$15.63

-0.39 (-2.43%)

NSANY

Nissan

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

CRMT

America's Car-Mart

$90.88

3.22 (3.67%)

, WUBA

58.com

$50.26

-1.35 (-2.62%)

18:38
11/18/19
11/18
18:38
11/18/19
18:38
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

CRMT

America's Car-Mart

$90.88

3.22 (3.67%)

WUBA

58.com

$50.26

-1.35 (-2.62%)

BILI

Bilibili

$16.39

-0.32 (-1.92%)

SAEX

SAExploration

$1.51

-0.05 (-3.21%)

CLVS

Clovis

$7.05

0.68 (10.68%)

NOW

ServiceNow

$266.56

6.65 (2.56%)

OKTA

Okta

$121.21

3.76 (3.20%)

SPLK

Splunk

$122.64

3.49 (2.93%)

WWD

Woodward

$113.64

-1.15 (-1.00%)

KRNT

Kornit Digital

$33.07

-1.13 (-3.30%)

ASH

Ashland

$78.65

0.03 (0.04%)

VNET

21Vianet

$8.28

0.23 (2.86%)

DHT

DHT Holdings

$7.52

-0.2 (-2.59%)

KRTX

Karuna Therapeutics

$94.70

77.44 (448.67%)

EGHT

8x8, Inc.

$20.78

0.13 (0.63%)

I

Intelsat

$7.98

-5.42 (-40.45%)

PFGC

Performance Food Group

$46.09

-0.08 (-0.17%)

EFC

Ellington Financial

$18.79

0.01 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 16

    Dec

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

LEVI

Levi Strauss

$17.06

-0.115 (-0.67%)

18:31
11/18/19
11/18
18:31
11/18/19
18:31
Hot Stocks
Levi Strauss CEO: I believe in the importance of innovation »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$45.17

0.07 (0.16%)

18:17
11/18/19
11/18
18:17
11/18/19
18:17
Periodicals
Cisco sues former employees over claims of trade secret theft, Bloomberg says »

Cisco is suing two…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 10

    Dec

  • 12

    Feb

ABBV

AbbVie

$88.71

0.07 (0.08%)

18:09
11/18/19
11/18
18:09
11/18/19
18:09
Hot Stocks
AbbVie treatment of myelofibrosis granted FDA orphan status »

AbbVie's navitoclax…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

PRQR

ProQR Therapeutics

$6.27

-0.64 (-9.26%)

18:06
11/18/19
11/18
18:06
11/18/19
18:06
Hot Stocks
ProQR Therapeutics treatment of retinal dystrophy in P23H granted orphan status »

ProQR Therapeutics'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:04
11/18/19
11/18
18:04
11/18/19
18:04
Earnings
Bilibili sees Q4 revenue RMB1.93B-RMB1.98B »

Q4 revenue consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

WUBA

58.com

$50.26

-1.35 (-2.62%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Earnings
58.com sees Q4 revenue up 12%-15% in RMB terms »

Based on the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Hot Stocks
Bilibili reports average MAUs reached 127.9M in Q3 »

Average monthly active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

WUBA

58.com

$50.26

-1.35 (-2.62%)

18:03
11/18/19
11/18
18:03
11/18/19
18:03
Earnings
58.com reports Q3 adjusted EPS 96c, consensus 82c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BILI

Bilibili

$16.39

-0.32 (-1.92%)

18:01
11/18/19
11/18
18:01
11/18/19
18:01
Earnings
Bilibili reports Q3 adjusted EPS (15c), consensus (14c) »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

DDOG

Datadog

$40.36

-0.33 (-0.81%)

, AMZN

Amazon.com

$1,752.70

15.21 (0.88%)

17:56
11/18/19
11/18
17:56
11/18/19
17:56
Hot Stocks
Datadog announces support for AWS CloudFormation Registry and CLI »

Datadog (DDOG) announced…

DDOG

Datadog

$40.36

-0.33 (-0.81%)

AMZN

Amazon.com

$1,752.70

15.21 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

17:55
11/18/19
11/18
17:55
11/18/19
17:55
Conference/Events
Morgan Stanley analyst to hold an analyst/industry conference call »

Managing Director &…

GVA

Granite Construction

$26.50

-0.6 (-2.21%)

17:54
11/18/19
11/18
17:54
11/18/19
17:54
Hot Stocks
Granite Construction awarded $14M airfield improvement project in California »

Granite announced it was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZS

Zscaler

$44.46

-1.37 (-2.99%)

, MSFT

Microsoft

$150.35

0.4 (0.27%)

17:51
11/18/19
11/18
17:51
11/18/19
17:51
Initiation
Zscaler, Microsoft initiated  »

Zscaler initiated with a…

ZS

Zscaler

$44.46

-1.37 (-2.99%)

MSFT

Microsoft

$150.35

0.4 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 04

    Dec

  • 09

    Dec

  • 16

    Dec

OKTA

Okta

$121.21

3.76 (3.20%)

17:51
11/18/19
11/18
17:51
11/18/19
17:51
Upgrade
Okta rating change  »

Okta pullback represents…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 16

    Dec

PANW

Palo Alto Networks

$248.50

1.465 (0.59%)

17:48
11/18/19
11/18
17:48
11/18/19
17:48
Initiation
Palo Alto Networks initiated  »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Nov

  • 09

    Dec

CRWD

Crowdstrike

$57.06

-2.73 (-4.57%)

, AMZN

Amazon.com

$1,752.70

15.21 (0.88%)

17:47
11/18/19
11/18
17:47
11/18/19
17:47
Initiation
Crowdstrike, Amazon.com initiated  »

Crowdstrike valuation…

CRWD

Crowdstrike

$57.06

-2.73 (-4.57%)

AMZN

Amazon.com

$1,752.70

15.21 (0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

  • 05

    Dec

  • 12

    Dec

TUFN

Tufin

$17.32

-0.22 (-1.25%)

17:44
11/18/19
11/18
17:44
11/18/19
17:44
Initiation
Tufin initiated  »

DA Davidson says Tufin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$122.64

3.49 (2.93%)

17:43
11/18/19
11/18
17:43
11/18/19
17:43
Initiation
Splunk initiated  »

Splunk initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SPCE

Virgin Galactic

$9.55

-0.075 (-0.78%)

17:42
11/18/19
11/18
17:42
11/18/19
17:42
Syndicate
Breaking Syndicate news story on Virgin Galactic »

Virgin Galactic files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

VIAV

Viavi

$15.74

-0.03 (-0.19%)

17:40
11/18/19
11/18
17:40
11/18/19
17:40
Hot Stocks
Viavi files patent suits against LG Electronics, LG Innotek, Optrontec »

Viavi filed a complaint…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.